Investigating the effect of omega-3 supplementation on inflammatory indices of dialysis patients

The Effect of Omega-3 Supplementation on Inflammatory Clinical Markers and Body Composition in Hemodialysis Patients A randomized, triple-blind, placebo- controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151226025699N6

Enrollment

120

Registered

2022-12-24

Start date

2022-11-06

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney failure undergoing hemodialysis. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: Omega-3 capsule contains 1000 mg of fish oil, 180 mg of EPA and 120 mg of DHA and auxiliary components of gelatin, glycerin, sodium methylparaben, sodium propylpara

The participants will be contacted again and will be invited and encouraged to complete the questionnaires and perform the tests. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Written consent Age over 20 years

Exclusion criteria

Exclusion criteria: No tendency to participate in the study Having incomplete medical records Consumption of omega-3 fatty acids supplementation during the last 3-month before the study

Design outcomes

Primary

Measure	Time frame
Body fat percentage. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated with a bio-impedance analyzer (BIA).;Dialysis itching. Timepoint: Before the intervention, after the intervention. Method of measurement: asking people and determining the intensity according to the Visual Analogue Scale.;Anemia rate based on KT/V calculation. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated based on measuring the level of hemoglobin.;Urea level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Creatinine level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum PTH level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Muscle mass. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated with a bio-impedance analyzer (BIA).;Hemodialysis quality based on KT/V calculation. Timepoint: Before the intervention, after the intervention. Method of measurement: Dialysis quality is measured in this center or the KT/V index. (K= Clearance, T= Time on HD, V= Volume of distribution of Urea).	—

Measure

Time frame

Body fat percentage. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated with a bio-impedance analyzer (BIA).;Dialysis itching. Timepoint: Before the intervention, after the intervention. Method of measurement: asking people and determining the intensity according to the Visual Analogue Scale.;Anemia rate based on KT/V calculation. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated based on measuring the level of hemoglobin.;Urea level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Creatinine level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum PTH level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Muscle mass. Timepoint: Before the intervention, after the intervention. Method of measurement: It is calculated with a bio-impedance analyzer (BIA).;Hemodialysis quality based on KT/V calculation. Timepoint: Before the intervention, after the intervention. Method of measurement: Dialysis quality is measured in this center or the KT/V index. (K= Clearance, T= Time on HD, V= Volume of distribution of Urea).

—

Secondary

Measure	Time frame
Cholesterol, triglyceride, and HDL and LDL serum levels. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum ferritin level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum albumin level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.	—

Measure

Time frame

Cholesterol, triglyceride, and HDL and LDL serum levels. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum ferritin level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.;Serum albumin level. Timepoint: Before the intervention, after the intervention. Method of measurement: serum level per milliliter of blood recorded in the laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Doaei

Tehran University of Medical Sciences

sdoaei@sbmu.ac.ir+98 21 6643 6744

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026